 Ahmet Eken
Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Regulatory | 9 | 2025 | 386 | 2.730 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 2025 | 68 | 1.900 |
Why?
| | Th17 Cells | 6 | 2023 | 107 | 1.700 |
Why?
| | Immunity, Innate | 8 | 2025 | 824 | 1.450 |
Why?
| | Lymphocytes | 6 | 2025 | 395 | 1.130 |
Why?
| | Multiple Sclerosis | 4 | 2021 | 460 | 0.990 |
Why?
| | Fingolimod Hydrochloride | 3 | 2022 | 40 | 0.900 |
Why?
| | Diet, Mediterranean | 1 | 2025 | 29 | 0.900 |
Why?
| | T-Lymphocyte Subsets | 3 | 2022 | 415 | 0.900 |
Why?
| | Mucosal-Associated Invariant T Cells | 2 | 2025 | 37 | 0.890 |
Why?
| | Thiamine | 1 | 2024 | 18 | 0.870 |
Why?
| | Leukocyte-Adhesion Deficiency Syndrome | 1 | 2023 | 2 | 0.830 |
Why?
| | Membrane Transport Proteins | 1 | 2024 | 152 | 0.790 |
Why?
| | Myasthenia Gravis | 1 | 2022 | 22 | 0.760 |
Why?
| | Receptors, Lysosphingolipid | 2 | 2022 | 15 | 0.740 |
Why?
| | Sphingosine | 1 | 2022 | 45 | 0.730 |
Why?
| | Placenta Accreta | 1 | 2022 | 29 | 0.720 |
Why?
| | Pancreatitis-Associated Proteins | 1 | 2021 | 6 | 0.710 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2022 | 66 | 0.700 |
Why?
| | Rheumatic Fever | 1 | 2021 | 11 | 0.690 |
Why?
| | Interleukins | 3 | 2023 | 246 | 0.680 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 461 | 0.680 |
Why?
| | Dietary Supplements | 1 | 2025 | 553 | 0.680 |
Why?
| | Toll-Like Receptor 7 | 1 | 2020 | 39 | 0.660 |
Why?
| | Interleukin-23 | 3 | 2022 | 19 | 0.650 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 138 | 0.640 |
Why?
| | Job Syndrome | 1 | 2019 | 7 | 0.640 |
Why?
| | Gaucher Disease | 3 | 2025 | 6 | 0.630 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2023 | 260 | 0.610 |
Why?
| | Cytokines | 8 | 2025 | 2080 | 0.550 |
Why?
| | Diabetes, Gestational | 1 | 2022 | 319 | 0.550 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 696 | 0.530 |
Why?
| | Genetic Association Studies | 1 | 2019 | 370 | 0.530 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 622 | 0.500 |
Why?
| | Gene Deletion | 1 | 2017 | 388 | 0.480 |
Why?
| | Mice | 15 | 2025 | 17814 | 0.480 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 431 | 0.480 |
Why?
| | Mutation | 9 | 2025 | 3987 | 0.470 |
Why?
| | Antiviral Agents | 2 | 2022 | 735 | 0.470 |
Why?
| | Hypertension | 1 | 2023 | 1242 | 0.430 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2023 | 72 | 0.420 |
Why?
| | Mice, Inbred C57BL | 8 | 2025 | 5798 | 0.410 |
Why?
| | Guanine Nucleotide Exchange Factors | 3 | 2019 | 64 | 0.390 |
Why?
| | Humans | 37 | 2025 | 138651 | 0.380 |
Why?
| | Animals | 19 | 2025 | 37217 | 0.380 |
Why?
| | Introns | 2 | 2024 | 254 | 0.370 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 1102 | 0.370 |
Why?
| | Exosomes | 2 | 2022 | 105 | 0.350 |
Why?
| | Obesity | 1 | 2024 | 2962 | 0.340 |
Why?
| | Dendritic Cells | 2 | 2011 | 491 | 0.340 |
Why?
| | Autoimmunity | 5 | 2025 | 903 | 0.330 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2339 | 0.330 |
Why?
| | Crohn Disease | 1 | 2014 | 251 | 0.320 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2024 | 428 | 0.320 |
Why?
| | Antigen Presentation | 1 | 2011 | 219 | 0.320 |
Why?
| | STAT5 Transcription Factor | 4 | 2025 | 57 | 0.310 |
Why?
| | Ethanol | 2 | 2011 | 614 | 0.310 |
Why?
| | Th1 Cells | 2 | 2019 | 139 | 0.280 |
Why?
| | Flow Cytometry | 3 | 2021 | 1192 | 0.260 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2025 | 27 | 0.230 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2024 | 31 | 0.220 |
Why?
| | Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 2024 | 1 | 0.220 |
Why?
| | Pyruvate Metabolism, Inborn Errors | 1 | 2024 | 1 | 0.220 |
Why?
| | Jurkat Cells | 1 | 2024 | 138 | 0.220 |
Why?
| | Disease Progression | 2 | 2023 | 2749 | 0.220 |
Why?
| | Pyruvate Kinase | 1 | 2024 | 26 | 0.220 |
Why?
| | Sesquiterpenes, Eudesmane | 1 | 2024 | 1 | 0.210 |
Why?
| | Autoimmune Lymphoproliferative Syndrome | 1 | 2023 | 1 | 0.210 |
Why?
| | Intestinal Absorption | 1 | 2024 | 92 | 0.210 |
Why?
| | Signal Transduction | 5 | 2025 | 5086 | 0.210 |
Why?
| | Case-Control Studies | 2 | 2024 | 3523 | 0.200 |
Why?
| | Lactones | 1 | 2024 | 58 | 0.200 |
Why?
| | Biomarkers | 4 | 2024 | 4092 | 0.200 |
Why?
| | Lymphoproliferative Disorders | 1 | 2023 | 58 | 0.200 |
Why?
| | Immunophenotyping | 1 | 2024 | 327 | 0.200 |
Why?
| | Intestine, Small | 1 | 2024 | 156 | 0.200 |
Why?
| | Reduced Folate Carrier Protein | 1 | 2022 | 10 | 0.200 |
Why?
| | Crotonates | 1 | 2022 | 5 | 0.200 |
Why?
| | Hydroxybutyrates | 1 | 2022 | 14 | 0.200 |
Why?
| | Leucovorin | 1 | 2022 | 85 | 0.190 |
Why?
| | T-Lymphocytes | 3 | 2024 | 1986 | 0.190 |
Why?
| | Female | 12 | 2025 | 73763 | 0.190 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 98 | 0.190 |
Why?
| | Benzyl Compounds | 1 | 2022 | 3 | 0.190 |
Why?
| | Cell Count | 1 | 2023 | 325 | 0.190 |
Why?
| | Lipomatosis | 1 | 2022 | 5 | 0.190 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2022 | 60 | 0.190 |
Why?
| | Bone Marrow Diseases | 1 | 2022 | 20 | 0.190 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2022 | 22 | 0.190 |
Why?
| | Propylene Glycols | 1 | 2022 | 27 | 0.190 |
Why?
| | Oxadiazoles | 1 | 2022 | 33 | 0.190 |
Why?
| | Granzymes | 1 | 2022 | 50 | 0.180 |
Why?
| | Child | 6 | 2025 | 21921 | 0.180 |
Why?
| | Azetidines | 1 | 2022 | 44 | 0.180 |
Why?
| | RNA Splice Sites | 1 | 2022 | 49 | 0.180 |
Why?
| | Nitriles | 1 | 2022 | 176 | 0.180 |
Why?
| | Graft vs Host Disease | 1 | 2024 | 253 | 0.180 |
Why?
| | Lysophospholipids | 1 | 2022 | 80 | 0.180 |
Why?
| | Nutritional Status | 1 | 2024 | 352 | 0.180 |
Why?
| | Thiophenes | 1 | 2022 | 122 | 0.170 |
Why?
| | Receptors, Interleukin | 1 | 2021 | 45 | 0.170 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2021 | 15 | 0.170 |
Why?
| | Pancytopenia | 1 | 2021 | 9 | 0.170 |
Why?
| | Interleukin-2 | 2 | 2025 | 451 | 0.170 |
Why?
| | Energy Intake | 1 | 2024 | 506 | 0.170 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2025 | 905 | 0.170 |
Why?
| | Ikaros Transcription Factor | 1 | 2021 | 24 | 0.170 |
Why?
| | Neutropenia | 1 | 2022 | 157 | 0.170 |
Why?
| | Common Variable Immunodeficiency | 1 | 2021 | 30 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 252 | 0.170 |
Why?
| | Child, Preschool | 4 | 2024 | 11158 | 0.170 |
Why?
| | Skin Cream | 1 | 2020 | 12 | 0.170 |
Why?
| | Vital Capacity | 1 | 2022 | 312 | 0.170 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 148 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 718 | 0.160 |
Why?
| | Forced Expiratory Volume | 1 | 2022 | 488 | 0.160 |
Why?
| | Models, Immunological | 1 | 2020 | 101 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2023 | 1098 | 0.160 |
Why?
| | Organ Specificity | 2 | 2017 | 310 | 0.160 |
Why?
| | Fetal Blood | 1 | 2022 | 336 | 0.160 |
Why?
| | Respiratory Function Tests | 1 | 2022 | 561 | 0.160 |
Why?
| | TYK2 Kinase | 1 | 2019 | 1 | 0.150 |
Why?
| | Consanguinity | 1 | 2019 | 49 | 0.150 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 741 | 0.150 |
Why?
| | Adjuvants, Immunologic | 1 | 2020 | 237 | 0.150 |
Why?
| | Apoptosis | 4 | 2023 | 2546 | 0.150 |
Why?
| | Dermatitis, Atopic | 1 | 2022 | 331 | 0.140 |
Why?
| | HEK293 Cells | 1 | 2021 | 728 | 0.140 |
Why?
| | Tissue Distribution | 1 | 2019 | 330 | 0.140 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 199 | 0.140 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 398 | 0.140 |
Why?
| | Pedigree | 1 | 2019 | 511 | 0.140 |
Why?
| | Lymphadenopathy | 1 | 2017 | 9 | 0.140 |
Why?
| | Lymphoid Tissue | 1 | 2017 | 79 | 0.130 |
Why?
| | Immunosuppressive Agents | 1 | 2022 | 849 | 0.130 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 352 | 0.130 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4315 | 0.130 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2172 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 675 | 0.120 |
Why?
| | Body Mass Index | 1 | 2024 | 2349 | 0.120 |
Why?
| | Disease Susceptibility | 1 | 2017 | 349 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 540 | 0.120 |
Why?
| | Placenta | 1 | 2022 | 753 | 0.120 |
Why?
| | Pandemics | 2 | 2022 | 1641 | 0.110 |
Why?
| | Male | 9 | 2025 | 68260 | 0.110 |
Why?
| | Kidney | 1 | 2023 | 1466 | 0.110 |
Why?
| | Turkey | 2 | 2024 | 21 | 0.110 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2014 | 14 | 0.110 |
Why?
| | Enterobacteriaceae Infections | 1 | 2014 | 43 | 0.110 |
Why?
| | Fetal Development | 1 | 2017 | 297 | 0.100 |
Why?
| | Inflammation | 3 | 2023 | 2850 | 0.100 |
Why?
| | Phenotype | 2 | 2021 | 3139 | 0.100 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5520 | 0.100 |
Why?
| | Infant | 5 | 2024 | 9574 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2590 | 0.090 |
Why?
| | Lymphocyte Activation | 2 | 2017 | 1148 | 0.090 |
Why?
| | Cell Proliferation | 1 | 2019 | 2480 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2019 | 4181 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2017 | 1470 | 0.090 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 411 | 0.080 |
Why?
| | Coculture Techniques | 1 | 2011 | 241 | 0.080 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2011 | 91 | 0.080 |
Why?
| | Pregnancy | 1 | 2022 | 6829 | 0.080 |
Why?
| | Lung | 1 | 2022 | 4106 | 0.070 |
Why?
| | Immune System | 1 | 2010 | 181 | 0.070 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2010 | 135 | 0.070 |
Why?
| | Hepacivirus | 1 | 2010 | 238 | 0.070 |
Why?
| | Middle Aged | 3 | 2025 | 33604 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2024 | 661 | 0.070 |
Why?
| | Adult | 3 | 2025 | 38201 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2019 | 3028 | 0.060 |
Why?
| | Glucosylceramidase | 1 | 2025 | 5 | 0.060 |
Why?
| | Enzyme Replacement Therapy | 1 | 2025 | 15 | 0.060 |
Why?
| | Phosphorylation | 2 | 2023 | 1760 | 0.060 |
Why?
| | Lymphocyte Count | 1 | 2025 | 166 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2025 | 101 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2025 | 101 | 0.060 |
Why?
| | Proton-Coupled Folate Transporter | 1 | 2022 | 10 | 0.050 |
Why?
| | Micronucleus Tests | 1 | 2022 | 7 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2024 | 406 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 314 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2024 | 292 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 136 | 0.050 |
Why?
| | Gain of Function Mutation | 1 | 2022 | 34 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 214 | 0.050 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2022 | 27 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 90 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2025 | 786 | 0.040 |
Why?
| | Folic Acid | 1 | 2022 | 184 | 0.040 |
Why?
| | Methotrexate | 1 | 2022 | 255 | 0.040 |
Why?
| | Adolescent | 3 | 2025 | 21564 | 0.040 |
Why?
| | NIH 3T3 Cells | 1 | 2021 | 148 | 0.040 |
Why?
| | Microfilament Proteins | 1 | 2021 | 132 | 0.040 |
Why?
| | Hydrogen Peroxide | 1 | 2022 | 331 | 0.040 |
Why?
| | Point Mutation | 1 | 2021 | 236 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2022 | 334 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 1935 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2017 | 1731 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2025 | 1244 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 571 | 0.040 |
Why?
| | DNA Damage | 1 | 2022 | 422 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2024 | 6144 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2022 | 607 | 0.040 |
Why?
| | Receptors, Interleukin-12 | 1 | 2019 | 7 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2023 | 476 | 0.040 |
Why?
| | Gene Knock-In Techniques | 1 | 2019 | 56 | 0.040 |
Why?
| | Interleukin-12 | 1 | 2019 | 123 | 0.040 |
Why?
| | Interferon Type I | 1 | 2019 | 141 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 649 | 0.030 |
Why?
| | Oxygen | 1 | 2022 | 977 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1765 | 0.030 |
Why?
| | Proteins | 1 | 2022 | 1006 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2019 | 230 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1262 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2022 | 1316 | 0.030 |
Why?
| | Young Adult | 2 | 2025 | 13305 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2017 | 366 | 0.030 |
Why?
| | Citrobacter rodentium | 1 | 2014 | 7 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 513 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2014 | 118 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2019 | 855 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2014 | 325 | 0.020 |
Why?
| | Colon | 1 | 2014 | 284 | 0.020 |
Why?
| | Sequence Analysis, RNA | 1 | 2014 | 448 | 0.020 |
Why?
| | Thioacetamide | 1 | 2011 | 3 | 0.020 |
Why?
| | B7-2 Antigen | 1 | 2011 | 28 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2113 | 0.020 |
Why?
| | B7-1 Antigen | 1 | 2011 | 58 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1123 | 0.020 |
Why?
| | Rats, Long-Evans | 1 | 2011 | 122 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2011 | 267 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2011 | 147 | 0.020 |
Why?
| | CD40 Antigens | 1 | 2011 | 89 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7554 | 0.020 |
Why?
| | Spleen | 1 | 2011 | 523 | 0.020 |
Why?
| | Hepatocytes | 1 | 2010 | 211 | 0.020 |
Why?
| | Hepatitis C | 1 | 2010 | 246 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2024 | 15909 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2010 | 335 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 2010 | 712 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5594 | 0.010 |
Why?
|
|
Eken's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|